AUTHORS
Michael Wang, Matthew J. Newman, PharmD, MEHP, BCOP2, Carmen Nobre, PharmD3, Gabrielle T. Prince, MD4, Khaled El-Shami, MD5, Ivana Gojo, MD6, B. Douglas Smith, MD7, Alexander Joseph Ambinder, MD, MPH8, Tania Jain, MBBS9, Theodoros Karantanos, MD, PhD10, Gabriel Ghiaur, MD, PhD11, William Brian Dalton, MD, PhD12, Lukasz P. Gondek, MD, PhD13, Amy DeZern, MD, MHS14, Mark J. Levis I, MD PhD15, Jonathan Allen Webster, MD16
AFFILIATIONS
1 University of Cincinnati, Cincinnati, Ohio, United States
2 Johns Hopkins University, Baltimore, Maryland, United States
3 Johns Hopkins University, Baltimore, Maryland, United States
4 Johns Hopkins University, Baltimore, Maryland, United States
5 Johns Hopkins University, Baltimore, Maryland, United States
6 Johns Hopkins University, Baltimore, Maryland, United States
7 Johns Hopkins University, Baltimore, Maryland, United States
8 Johns Hopkins University, Baltimore, Maryland, United States
9 Johns Hopkins University, Baltimore, Maryland, United States
10 Johns Hopkins University, Baltimore, Maryland, United States
11 Johns Hopkins University, Baltimore, Maryland, United States
12 Johns Hopkins University, Baltimore, Maryland, United States
13 Johns Hopkins University, Baltimore, Maryland, United States
14 Johns Hopkins University, Baltimore, Maryland, United States
15 Johns Hopkins University, Baltimore, Maryland, United States
16 Johns Hopkins University, Baltimore, Maryland, United States
ABSTRACT
Background: Activating mutations in FLT3 and IDH1/2 co-occur in a subset of AML patients and contribute to therapeutic resistance. In the Phase III ADMIRAL trial, 15.5% of patients with relapsed FLT3-mutated AML had an IDH1 or IDH2 mutation, and the response rate to gilteritinib in these patients was 28.2% (Smith. Blood Advances. 2022). Concurrent inhibition of both pathways is a rational therapeutic strategy. Given a lack of data, we evaluated the safety, tolerability, and outcomes of combination therapy with gilteritinib and an IDH inhibitor in FLT3 and IDH-mutated AML.
Methods: Patients ≥18 years old with AML harboring concurrent FLT3 and IDH1 or IDH2 mutations who received gilteritinib/ivosidenib (G/I) or gilteritinib/enasidenib (G/E) and were treated at Johns Hopkins from October 2019 – July 2026 were included. Baseline patient, disease, and treatment characteristics were collected, including prior therapies and prior allogeneic blood or marrow transplantation (alloBMT). Treatment exposure, grade 3-4 adverse events (AEs), duration of combination therapy, and survival outcomes were evaluated. Response assessments were categorized according to European LeukemiaNet (ELN) criteria. Estimators of overall survival (OS) were reported using the Kaplan-Meier method.
Results: Twenty-eight patients with FLT3-mutated AML were identified including 14 each with IDH1 and IDH2 mutations treated with G/I or G/E, respectively. Median age at therapy initiation was 64.8 years (range, 28-90). The majority of patients (68%) had FLT3-ITD mutations and the remainder (32%) had FLT3-TKD mutations. Among those treated, 13 received combination therapy to maintain remission (G/I 8, G/E 5) including 3 as post-alloBMT maintenance and 3 as a bridge to alloBMT, 13 for relapsed disease (G/I 6, G/E 7), and 2 for persistent MRD (G/E 2). Patients had received a median of one prior line of therapy (range, 1-3); 57% had previously received intensive induction, 54% hypomethylating agent-based therapy with or without venetoclax, 43% a prior FLT3 inhibitor, 7% a prior IDH inhibitor(I, n=1; E, n=1), and 29% prior alloBMT.
The median duration of combination therapy was 7.7 months (range, 0.5-44.4), including 22.9 months for those in remission and 2.5 months in the relapsed/refractory cohort. Eight patients remained on combination therapy at last follow-up. Among those who discontinued therapy, reasons for discontinuation included death (6), progressive disease (4), infection (3), side effects/patient choice (3), alloBMT (3), and provider decision (1). Grade 3-4 differentiation syndrome occurred in one patient (4%), while grade 3-4 hepatotoxicity occurred in three patients (11%). The most common grade 3-4 AEs were thrombocytopenia (57%), anemia (54%), and neutropenia (43%). However, none of the patients in remission at the time of treatment initiation had sustained (>30 days) grade 3-4 hematologic toxicities.
Among the 13 relapsed patients, three patients achieved remission (23%). Among six patients with relapsed or refractory disease on combination therapy, repeat NGS testing at the time of disease progression revealed loss of both FLT3-TKD and IDH1 (1), loss of FLT3-ITD alone (1), gain of IDH2 in addition to known FLT3-ITD and IDH1 mutations (1), gain of FLT3-ITD in addition to known FLT3-TKD and IDH2 mutations, a new CSF3R mutation (1), and no significant changes (1). Overall, 17 patients achieved confirmed remission during the course of combination therapy, including 14 patients with confirmed remission at treatment initiation and three patients who achieved remission after starting combination therapy. Among these 17 patients, 16 had MRD testing with either NPM1 PCR (4), FLT3-ITD PCR (9), or both (3) of whom 14 were MRD-negative (87.5%). Two-year OS from the initiation of combination therapy was 9.6% in patients treated for relapsed disease and 85.6% for all other indications (HR 15.3 (95% CI 3.2-72.3), p=0.001) including 83.3% for the 7 patients (G/I 4, G/E 3) treated as maintenance in CR1 without alloBMT.
Conclusions: Concurrent FLT3 and IDH inhibition with G/I or G/E was feasible and well tolerated. Dynamic changes in driver mutations were seen in patients progressing on therapy, while sustained MRD-negativity by NPM1 or FLT3-ITD PCR was seen in responding patients. With expanding targeted therapy options, prospective studies are needed to determine the optimal implementation of combination strategies.
DISCLOSURES
Jonathan Allen Webster, MD: Autolus - Honoraria; Syndax - Honoraria; Rigel - Honoraria; Amgen - Honoraria; AstraZeneca - Honoraria; CVS - Consultancy (Includes expert testimony)